TF
RARE icon

Trek Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

Trek Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,436
Closed -$205K – 264
2021
Q4 		$205K Buy
+2,436
New +$198K 0.02% 199

Other funds holding RARE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Trek Financial's RARE Position: Q1 2022 in Review

Trek Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2022, closing a stake of 2,436 shares — an estimated $205K sold.

Trek Financial first reported a position in RARE in Q4 2021 and held it in 1 quarter. The position peaked at $205K in Q4 2021. 239 funds tracked by Wall St. Rank hold RARE as of Q1 2022.

  • Trek Financial reported no remaining Ultragenyx Pharmaceutical position as of Q1 2022 after selling out during the quarter.
  • Trek Financial sold 2,436 Ultragenyx Pharmaceutical shares in Q1 2022, an estimated $205K.
  • Trek Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2021 and held it in 1 quarter.
  • Trek Financial's Ultragenyx Pharmaceutical position peaked at $205K in Q4 2021.
  • 239 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2022.

Based on Trek Financial's 13F filing for Q1 2022, filed 10 May 2022.